Royalty Report: Drugs, Biotechnology, Pharmaceuticals – Collection: 4499


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4499

License Grant
The license grants the worldwide, exclusive right to develop, manufacture, use and sell, and offer for sale products covered by a suite of patents and patent applications covering the composition of matter for eight individual lysin molecules for the treatment and prevention of diseases caused by gram-positive bacteria.
License Property
The lysins in this suite have activity against Staphylococcus, Group A Streptococcus, Group B Streptococcus, Pneumococcus, Enterococcus and Anthrax.

IPSCIO Record ID: 4498

License Grant
This Agreement is between a University and the Licensee. The agreement is for the worldwide, exclusive right to a provisional patent application, upon which a non-provisional patent application has since been filed, covering the composition of matter for the lysin PlySS2 for the treatment and prevention of diseases caused by gram-positive bacteria. The Licensee has re-branded PlySS2 as CF-301.  The grant covers the rights to discover, develop, make, have made, use, import, lease, sell and offer for sale Licensed Products and (ii) to use University Technical Information and University Materials to discover, develop, make, have made, use, import, lease, sell and offer for sale Licensed Products. The License is granted solely in the Field of Use during the Term, and include the right to sublicense under conditions specified in the agreement.
License Property
Intellectual property from the University includes the following  
1. DNA clones of PlySS1 and PlySS2; 2. Small quantities of these respective lysin proteins (1-5 mg) if available; 3. Polyclonal rabbit antiserum (1-5 ml) to each lysin when available; 4. Bacterial strain for each lysin that is sensitive to the respective lysin.
Field of Use
Field of Use means prophylactic and therapeutic use of lysins in humans. Field of Use expressly excludes the use of lysins directly or indirectly for vaccines, small molecule antibiotics, laboratory reagents, or diagnostic purposes.

IPSCIO Record ID: 29062

License Grant
The Licensor granted exclusive worldwide License to the Licensee has obtained the right and License to make, use and sell mucosal vaccines based on gram-positive organisms and products for the therapy, prevention and diagnosis of diseases caused by streptococcus, staphylococcus and other organisms. The License covers eight issued U.S. patents and three issued European patents, as well as one pending U.S. patent application and one pending European application. The issued United States patents expire in 2008, 2014 (4), 2015 (2), and 2016, respectively.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.